跳至主要内容
临床试验/JPRN-C000000197
JPRN-C000000197已完成未知

Efficasy of combination therapy PEG-IFN-alpha-2b and Ribavirin for patients with Serogroup1 and high titer HCV. - Combination therapy of PEG-IFN-alpha-2b and Ribavirin.(Serogoup1 and high titer)

Osaka university graduate school of medicine0 个研究点目标入组 500 人开始时间: 2008年12月31日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Pregnant or lactating women and women who may be pregnant Female patients or male patients with partners who may become pregnant who cannot practice contraception during treatment and 6 months after end of treatment Male patients with pregnant partners who cannot comply with condom use during treatment and 6 months after end of treatment History of hypersensitivity to ribavirin or other nucleoside analogs Inadequately controlled cardiac disease Hemoglobinopathy Chronic renal failure or renal function disorder with creatinine clearance of 50 ml/min or less With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. Serious hepatic function disorder Autoimmune hepatitis History of hypersensitivity to PEG-IFN alfa-2b or other interferons History of hypersensitivity to biological products such as vaccine Patients receiving shosaikoto Judged by investigator to be not appropriate for inclusion in study

研究者

相似试验

Efficasy of combination therapy PEG-IFN-alpha-2b and... | 临床试验